XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. (XERS) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | D+ (1.8) | B- (3.1) | B+ (3.5) | A (4.4) | C+ (2.6) | B- (3.1) |
| 2026-11-08 | D+ (1.8) | B- (3.0) | B+ (3.7) | A- (4.1) | C+ (2.6) | B- (3.1) |
| 2026-11-01 | C- (2.0) | B+ (3.5) | B+ (3.7) | B+ (3.8) | C+ (2.7) | B- (3.1) |
| 2026-10-25 | C- (2.1) | B+ (3.5) | B+ (3.6) | B+ (3.6) | C+ (2.6) | B- (3.1) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe